POSTER SESSION VI Wednesday, March 26, 2003   —  1:00 - 4:00 PM Exhibit Hall A - C DERMATOPATHOLOGY 64 Assessment of T Cell Clonality Via a Single Stranded DNA Polymorphism Conformational Assay (449) M Srinivasan, RW Werling, RS Phillips, N Ahmad, D Vlassov, AN Crowson, MC Mihm, CM Magro The Ohio State University, Columbus, OH; Regional Medical Laboratory, University of Oklahoma, Tulsa, OK; Massachusetts General Hospital, Boston, MA 65 Primary Cutaneous T-Cell Rich CD30+ Large Cell B-Cell Lymphoma: A Series of Cases Describing a Distinct Clinicopathologic Disease Entity (455) RW Werling, AN Crowson, MC Mihm, RS Phillips, NM Ahmad, D Vlassov, P Porcu, C Magro The Ohio State University, Columbus, OH; Regional Medical Laboratory, University of Oklahoma, Tulsa, OK; Massachusetts General Hospital, Boston, MA 66 Expression of the bcl-6 Protein Correlates with Overall Survival in Patients with Primary Cutaneous Large B Cell Lymphoma (450) U Sundram, S Mraz-Gerhard, M Storz, Y Natkunam, R Hoppe, Y Kim, S Kohler Stanford University Medical Center, Stanford, CA 67 Cutaneous T-Cell Lymphomas Other Than Mycosis Fungoides and CD30-Positive Lymphomas: A Survey of Histologic Types, Clinical Features, and Cytotoxic Protein (CP) Expression (435) RM Patel, J McDonnell, ED Hsi Cleveland Clinic, Cleveland, OH 68 Intravascular Large B Cell Lymphoma Involving a Capillary Hemangioma: An Unusual Presentation of a Rare Neoplasm (430) BK Nixon, SJ Kussick, M Carlon, BP Rubin University of Washington, Seattle, WA; Group Health Cooperative Hospital, Seattle, WA 69 Cutaneous Immunocytoma: A Clinical Histologic and Phenotypic Study of 8 Cases (386) NM Ahmad, AN Crowson, MC Mihm, D Vlassov, RW Werling, RS Phillips, C Magro The Ohio State University, Columbus, OH; Regional Medical Laboratory, University of Oklahoma, Tulsa, OK; Massachusetts General Hospital, Boston, MA 70 Pilar Melanocytic Tumor: A Rare Biphasic Neoplasm (395) HM Chen, DM Berney, M Medenica, A Montag, T Krausz The University of Chicago Hospitals, Chicago, IL; St Bartholomew's Hospital, London, UK 71 Proliferative Activity in Melanocytic Nevi from Patients Grouped by Age (420) D Lu, B Hoch, LP Dehner, AC Lind Washington University at St Louis, St Louis, MO; Massachussetts General Hospital, Boston, MA 72 Oncocytic Melanoma: An Ultrastructural and Prognostic Study (448) S Somach, MB Morgan Case Western, Cleveland, OH; South Florida Colleges of Medicine, Tampa, FL 73 Mast Cells Associated with Spindle Cell Morphology in Primary Cutaneous Melanoma (423) M Mahdavy, BR Smoller University of Arkansas for Medical Sciences, Little Rock, AR 74 Laminin-5 Expression in Melanocytic Lesions of the Skin (440) JA Ramirez, K Wang, MS Rao, L Diaz Feinberg School of Medicine Northwestern University, Chicago, IL 75 Microphthalmia Transcription Factor (Mitf), Mart-1, HMB-45, and S100 Expression in Radial Growth Phase Melanoma (415) R King, PB Googe, RN Page, MC Mihm, Jr Knoxville, TN; University of Tennessee Graduate School of Medicine, Knoxville, TN; Massachusetts General Hospital, Boston, MA 76 Expression of c-met Tyrosine-Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas (401) J Cruz, JS Reis-Filho, JM Lopes Hospital S. Joao, Porto, Portugal; IPATIMUP, Porto, Portugal; School of Health Sciences, University of Minho, Braga, Portugal; Porto Medical School, Porto, Portugal 77 Alteration of PTEN Expression May Not Involve Development of Melonoma: A Immunohistochemical Study (422) FF Luo, N Li, IP Shintaku, AJ Cochran, H Shen, SW Binder UCLA Medical Center, Los Angeles, CA; Yale University, New Haven, CT 78 SKP2 and p27 Are Inversely Related in Melanoma (418) Q Li, WA Lavezzi, DM Vincenti, CE Sheehan, JS Ross, JA Carlson Albany Medical College, Albany, NY 79 The Detection of Sentinel Node Micrometastases of Coutaneus Melanoma Is Facilitated by the Use of Monoclonal Antibody to S-100 Protein Alpha Subunit (425) G Mazzarol, P Dell'Orto, M Chilosi, G Viale European Institute of Oncology and University of Milan School of Medicine, Milan, Italy; University of Verona, Milan, Italy 80 Can Melan-A Replace S100 and HMB45 in Evaluation of Sentinel Lymph Nodes from Patients with Melanoma? (457) X Xu, E Williams, PJ Zhang University of Pennsylvania, Philadelphia, PA 81 Prognostic Factors Predict Non-Sentinel Node Status in Melanoma Patients (454) D-R Wen, R-R Huang, H Starz, H-J Wang, DL Morton, AJ Cochran UCLA School of Medicine, Los Angeles, CA; Klinikum Augsburg, Augsburg, Germany; John Wayne Cancer Institute, Santa Monica, CA 82 Expression of Cancer-Testis Antigens in Metastatic Malignant Melanoma (392) KJ Busam, K Iversen, AA Jungbluth Memorial Sloan-Kettering Cancer Center, New York, NY; Ludwig Institute, New York, NY 83 An Immunohistochemical Tissue Microarray Study of Primary and Metastatic Malignant Melanoma: Is Antigenic Shift a Common Occurrence in Metastatic Melanoma? (436) JA Plaza, DM Perez-Montiel, S Suster Ohio State University Medical Center, Columbus, OH